Serina Therapeutics announces agreement to access up to $20M in financing

Serina Therapeutics (SER) announced that it has entered into an agreement to access up to $20M in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised, could result in additional proceeds of up to $20M. Under the terms of the agreement, Serina may draw on up to $20M through an unsecured convertible note to be issued in five tranches, tied to clinical and operational milestones. “This financing provides the resources to advance SER-252 through critical clinical milestones on the path toward registration,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “Importantly, the structure allows us to deploy capital in step with trial progress, while maintaining flexibility to access additional non-dilutive and strategic funding. We believe SER-252 has the potential to transform treatment for those with advanced Parkinson’s disease.”